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For a long time, pioneers in the field of cancer cell metabolism, such as Otto
Warburg, have focused on the idea that tumor cells maintain high glycolytic rates
even with adequate oxygen supply, in what is known as aerobic glycolysis or the
Warburg effect. Recent studies have reported a more complex situation, where the
tumor ecosystem plays a more critical role in cancer progression. Cancer cells
display extraordinary plasticity in adapting to changes in their tumor microenvironment,
developing strategies to survive and proliferate. The proliferation of cancer cells needs a
high rate of energy and metabolic substrates for biosynthesis of biomolecules. These
requirements are met by the metabolic reprogramming of cancer cells and others
present in the tumor microenvironment, which is essential for tumor survival and
spread. Metabolic reprogramming involves a complex interplay between oncogenes,
tumor suppressors, growth factors and local factors in the tumor microenvironment.
These factors can induce overexpression and increased activity of glycolytic isoenzymes
and proteins in stromal and cancer cells which are different from those expressed in
normal cells. The fructose-6-phosphate/fructose-1,6-bisphosphate cycle, catalyzed by
6-phosphofructo-1-kinase/fructose 1,6-bisphosphatase (PFK1/FBPase1) isoenzymes,
plays a key role in controlling glycolytic rates. PFK1/FBpase1 activities are allosterically
regulated by fructose-2,6-bisphosphate, the product of the enzymatic activity of
the dual kinase/phosphatase family of enzymes: 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatase (PFKFB1-4) and TP53-induced glycolysis and apoptosis regulator
(TIGAR), which show increased expression in a significant number of tumor types. In
this review, the function of these isoenzymes in the regulation of metabolism, as well as
the regulatory factors modulating their expression and activity in the tumor ecosystem
are discussed. Targeting these isoenzymes, either directly or by inhibiting their activating
factors, could be a promising approach for treating cancers.
Keywords: fructose 2,6-bisphosphate, cancer metabolism, glycolysis, PFKFB isoenzymes, TIGAR, tumor
microenvironment
INTRODUCTION
Otto Warburg, using the Warburg manometer to measure the oxygen consumption in cells,
demonstrated that tumor cells showed rapid and intense glycolysis, in which glucose was oxidized
into lactate, despite the presence of abundant oxygen (1). This “Warburg effect” is characteristic
of proliferating and transformed cells. Warburg postulated that cancer was a result of defects in
mitochondrial respiration, which forced the cell to adopt an anaerobic form of energy generation,
Bartrons et al. Fructose 2,6-Bisphosphate in Cancer Cell Metabolism
glycolysis (2). There are different molecular mechanisms that
can explain the Warburg effect, including: mitochondrial
malfunction (3), oncogenic alterations (4–7), as well as responses
to adapt to the tumor microenvironment (TME) (8–10). Even
though not all cancer cells have high glycolytic flux (11), the
Warburg effect has been observed in most tumor cells and
represents an adaptation to support biomass production (10).
At the same time as Otto Warburg, Herbert G. Crabtree
studied the heterogeneity of glycolysis in tumors, describing
that the magnitude and relationships between respiratory and
glycolytic processes were a common feature of uncontrolled
proliferation and not specific to malignant tissues (12). He
observed considerable variability between respiratory and
glycolytic metabolism among different tumors (13). Moreover, he
found that glycolytic activity significantly affected the respiration
capacity of tumor tissues being respiration and oxidative
phosphorylation inhibited by glucose (13). This observation,
referred as the “Crabtree effect,” might be advantageous to
cancer cells, allowing them to adjust their metabolism to
heterogeneous microenvironments in malignant cells, through
the glucose-dependent accumulation of essential metabolites,
such as serine, phosphoribosyl-pyrophosphate, and glycerol-3-
phosphate, which can trigger mitogenic events (11, 14, 15). The
Crabtree effect on tumor cells can be eliminated by adding an
excess of inorganic phosphate (Pi) (15, 16).
The resurgence of the role of bioenergetics in cancer began
in the early 1990s when studies using 2-deoxy-D-glucose (2-
DG) in positron emission tomography (PET) showed that
most tumors displayed increased glucose uptake in about an
order of magnitude higher than that of normal tissue (8). The
increased glucose uptake largely depends on the rate of glucose
Abbreviations: 2,3-BPG, 2,3-bisphosphoglycerate; 2-DG, 2-deoxy-D-glucose;
AML, acute myeloid leukemia; AMPK, AMP-activated protein kinase; APC/C,
anaphase-promoting complex; AR, androgen receptor; CAF, cancer-associated
fibroblast; CAV1, caveolin-1; CDK1, cyclin-dependent kinase 1; CML, chronic
myeloid leukemia; ConA, concanavalin A; CREB, CRE-binding protein; DRAM,
damage-regulated autophagy modulator; EC, endothelial cell; ECyd, 1-(3-
C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine; ER, estrogen receptor; ERE,
estrogen response element; FBPase1, fructose 1,6-bisphosphatase; FBPase-2,
fructose 2,6-bisphosphatase; Fru-1,6-P2, fructose-1,6-bisphosphate; Fru-
2,6-P2, fructose 2,6-bisphosphate; Fru-6-P, fructose-6-phosphate; GASC,
glioblastoma-associated stromal cell; GC, glucocorticoid; Glut1, glucose
transporter 1; HCC, hepatocellular carcinoma; HIF-1α, hypoxia inducible
factor-1α; HK-2, hexokinase-II; IL-6, interleukin-6; LPS, lipopolysaccharide;
LUBAC, linear ubiquitination assembly complex; MACC1, metastasis-associated
in colon cancer protein 1; MAPK-1, mitogen-activated protein kinase 1;
MCT4, metabolic coupling monocarboxylate transporter 4; NFκB, nuclear
factor κB; PDK1, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvate;
PEPCK1, phosphoenolpyruvate carboxykinase 1; PET, positron emission
tomography; PFK1, 6-phosphofructo-1-kinase; PFK1/FBPase1, 6-phosphofructo-
1-kinase/fructose 1,6-bisphosphatase; PFK-2, 6-phosphofructo-2-kinase;
PFK-2/FBPase-2, 6-fosfofructo-2-kinase/fructose 2,6-bisphosphatase; PGAM,
phosphoglycerate mutase; PKA, cAMP-dependent protein kinase; PKB, protein
kinase B; PKM2, pyruvate kinase isoenzyme M2; PP-1, protein phosphatase 1;
PPARγ, peroxisome proliferator-activating receptor γ; PPP, pentose phosphate
pathway; PR, progesterone receptor; PRE, progesterone response element;
RB, retinoblastoma; ROBO1, round about guidance receptor 1; ROS, reactive
oxygen species; RSK, p90 ribosomal S6 kinase; SCNC, small cell neuroendocrine
carcinoma; SCO2, cytochrome C-oxidase-2; SLIT2, slit guidance ligand 2; SP1,
specificity protein 1; SRC-3; steroid receptor coactivator-3; TGF-β1, transforming
growth factor beta 1; TIGAR, TP53-induced glycolysis and apoptosis regulator;
TME, tumor microenvironment; VEGF, vascular endothelial growth factor.
phosphorylation by hexokinases and the upregulation of glucose
transporters Glut1 andGlut3 and less oftenGlut4 (17).More than
90% of primary and metastatic tumors have high glucose uptake,
which directly correlates with tumor aggressiveness (8, 18).
For a long time, studies on cancer cell metabolism had focused
on investigating a single cell type. However, recent studies
have reported a more complex situation in which metabolic
heterogeneity within tumors plays a critical role in cancer
progression (19–21). Cancer cells display extraordinary plasticity
in adapting to changes in their TME, developing strategies to
survive and proliferate. Interactions between tumor cells and
non-malignant cells of the TME influence cancer initiation
and progression as well as patient prognosis (22–24). Local
differences in the TME, including acidity and hypoxia, affect
cancer cells progression. If located close to blood vessels, cancer
cells can proliferate at a higher rate because of the abundant
supply of nutrients, growth factors and oxygen. By contrast,
if the supply of nutrients and oxygen is reduced, cancer cells
rely more on glycolysis, forcing them to develop strategies
for survival and proliferation. Thus, it is not surprising that
these cells in metabolically deprived environments are usually
chemoresistant and have higher malignancy grades (25). Stromal
cells, especially cancer-associated fibroblasts (CAFs), influence
the homeostasis of the TME. The interactions between TME and
cancer cells strongly affect tumor metabolism and growth (26–
29). A “two-compartment” model, referred to as the “reversed
Warburg effect,” has been proposed as a new perspective of
tumor metabolism in which tumor stroma and adjacent host
tissues are catabolic, while cancer cells are anabolic (19–21, 28–
30). Energy is transferred from the catabolic to the anabolic
compartment via the sharing of nutrients, which promotes
tumor growth. Although lactate is generally considered a waste
product, it has been demonstrated to fuel oxidative metabolism
in cancer cells, favoring a symbiosis between glycolytic and
oxidative tumor cells (19–21, 28–30). Metabolic reprogramming
of cancer and stromal cells involves a complex interplay between
oncogenes, tumor suppressors, growth factors and local factors
from the TME. These factors can induce the overexpression and
increased activity of isoenzymes and other proteins in cancer
cells that are different from those found in non-malignant
cells (30).
REPROGRAMMING THE GLYCOLYTIC
PHENOTYPE OF CANCER CELLS
Most tumor cells have a markedly modified energymetabolism in
comparison to differentiated cells. Their metabolism, previously
based on respiration, changes to another eminently glycolytic,
recognized as the glycolytic phenotype (7, 31–34). Several
glycolytic genes are usually overexpressed in many tumors and
give place to this phenotype (35). This occurs because tumor
cells reprogram cellular metabolism increasing the transcription
and/or alternative splicing of glycolytic genes induced by
the Hypoxia Inducible Factor-1α (HIF-1α), oncogenes and
inactivated tumor suppressor genes and distinct growth
factors (34, 36–39). The glycolytic phenotype is a distinctive
characteristic of tumor cells (7, 31, 33), providing advantages
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to proliferating cells and allowing them to metabolize the most
plentiful nutrient, glucose, to generate energy and anabolic
precursors. Even though the yield of ATP per glucose molecule
consumed is low, the percentage of cellular ATP generated
from glycolysis can surpass that produced from oxidative
phosphorylation if the glycolytic flux is high enough (11, 32, 40).
Furthermore, glucose metabolism provides intermediates that
are needed for biosynthetic pathways, such as ribose sugars for
nucleotide synthesis and hexose sugar derivatives, glycerol and
citrate for lipid production, non-essential amino acids (serine,
glycine, and cysteine) and NADPH. Therefore, the Warburg
effect has a positive impact on bioenergetics, biosynthesis and
detoxification of reactive oxygen species (ROS) (10).
There are several checkpoints regulating the acquisition of the
glycolytic phenotype. The first point of commitment of glucose-
6-phosphate to the glycolytic pathway involves the fructose-6-
phosphate/fructose-1,6-bisphosphate cycle (Fru-6-P/Fru-1,6-P2)
(41) (Figure 1). The following paragraphs describe the specific
isoenzymes regulating this substrate cycle, the main properties of
which are summarized in Table 1.
6-Phosphofructo-1-Kinase (PFK1)
PFK1 is a tetrameric protein, with three genes encoding
the PFK-M (muscle), PFK-L (liver), and PFK-P (platelet)
FIGURE 1 | Regulation of the fructose-6-P/fructose-1,6-P2 substrate cycle.
Fructose-2,6-P2 is synthesized and degraded by PFK-2/FBPase-2,
respectively. Increased levels of the metabolite activate PFK-1 and inhibit
FBPase1, increasing the glycolytic flux. Phosphorylation of the PFKFB2 and
PFKFB3 isoenzymes increases their kinase activity. The kinases and
phosphatases responsible for their regulation vary according to the isoenzyme.
PFKFB1 is not represented by this figure, as phosphorylation increases the
bisphosphatase activity of the enzyme. At present, PFKFB4 has not been
found to be regulated by phosphorylation.
human isoforms, with a molecular weight of their subunits
of 82.5, 77, and 86.5 kDa, respectively (42). The different
isoforms can form homo- or hetero-tetramers depending on
the cell type (38, 42). Lactate induces the dissociation of
the tetramers into dimers, reducing enzymatic activity and
providing negative feedback in the regulation of the glycolytic
rate (43). PFK1 isozymes can be phosphorylated by different
kinases but this does not produce significant catalytic effects
(41, 44, 45), although the covalent modification can affect their
association with other proteins (46–48). Localization to the
actin filaments of the cytoskeleton has been shown to increase
PFK-M activity (49), which can also bind to and modulate
protein phosphatase-1 (50). PFK-L, but not PFK-M and PFK-
P, assembles into filaments, with fructose-6-P binding essential
for their formation (51). These filaments have been observed
to localize in the plasma membrane, where they promote the
vessel sprouting of endothelial cells (52). PFK-L forms clusters
in human cancer cells and colocalizes with other rate-limiting
enzymes in both glycolysis and gluconeogenesis, supporting
the formation of multienzyme metabolic complexes for glucose
metabolism, integrating PFK-L, FBPase1, the pyruvate kinase
isoenzymeM2 (PKM2) and phosphoenolpyruvate carboxykinase
1 (PEPCK1), among others, and forming the “glycosome” (53).
PFK1 is also regulated by different allosteric effectors, which
provides control of the glycolytic flux and coordination of
glucose entry into glycolysis. It is a tightly-regulated enzyme
and its kinetic and regulatory characteristics depend on the
composition of its different subunits. Its regulation involves a
series of negative (citrate, ATP, phosphoenolpyruvate, and [H+])
and positive effectors (Fru-2,6-P2, AMP, Fru-1,6-P2, Glu-1,6-
P2, NH4+, and Pi) (41, 42), which coordinate its response
to the energy status of the cell. PFK1 activity increases in
response to proliferation signals alongside elevated glycolysis
in proliferating and cancer cells (54), although there are
exceptions where its activity does not increase (44, 54). The
main isoenzymes expressed in tumor cells are PFK-P and
PFK-L (54, 55). In human lymphomas and gliomas, PFK1
is less sensitive to inhibition by ATP and citrate, and more
sensitive to activation by Fru-2,6-P2 and AMP (44, 56). PFK1
activity is induced by HIF-1α (57) or the overexpression of
the oncogenes RAS and SRC (58). PFK-L and PFK-P can be
glycosylated in response to hypoxia, which inhibits PFK1 activity
and redirects the glucose flux toward the pentose phosphate
pathway (PPP), providing pentose sugars for nucleotide synthesis
and NADPH to combat oxidative stress (59). Similarly, the
transcription repressor Snail reprograms glucose metabolism by
repressing PFK-P, suppressing lactate production and amino
acids biosynthesis, while promoting cancer cell survival under
metabolic stress (60). Akt can bind to and phosphorylate PFK-P
at S386, which inhibits the binding of TRIM21 E3 ligase to
PFK-P and its subsequent polyubiquitylation and degradation.
This has been shown to increase PFK-P activity, glycolysis,
cell proliferation and brain tumor growth (48). Recently, EGFR
activation has been reported to elicit lysine acetyl-transferase-
5-mediated PFK-P acetylation and subsequent translocation of
PFK-P to the plasma membrane, where EGFR phosphorylates
PFK-P at Y64. Phosphorylated PFK-P binds to the N-terminal
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TABLE 1 | Properties of the glycolytic enzymes acting on Fru-6-P/Fru-1,6-P2 substrate cycle.
Protein Gene Chromosomal
location
(human)
Kinase/phosphatase
ratio
Isoenzymes Regulation
6-phosphofructokinase (PFK1) PFK-M 12q13.11 Only kinase PFK-M (muscle) PKA, PKC and AMPK in
rabbit, rat, and pig,
respectively
PFK-L 21q22.3 Only kinase PFK-L (liver) Ras, Src, HIF1α
PFK-P 10p15.2 Only kinase PFK-P
(platelets)
Akt, EGFR, HIF-1α
Glycosylation, Snail
Fructose-1,6-bisphosphatase
(FBPase)
FBPase1 9q22.32* Only
phosphatase
FBPase1 Snail
FBPase2 9q22.32* Only
phosphatase
FBPase2 Not described
6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase
(PFK-2/FBPase-2)
PFKFB1 Xp11.21 2.5 (rat liver) 1.2
(bovine liver)
0.4 (rat muscle)
lPFK-2 (liver)
mPFK-2
(muscle)
fPFK-2 (fetal)
PKA
PP-1
PFKFB2 1q32.1 1.8 (bovine
heart)
hPFK-2 (heart) AMPK, PKA, Akt, PKC, RSK
Glucocorticoids, androgens,
RNA LINC00092
PFKFB3 10p15.1 710 (human
placenta)
3.1 (bovine
brain)
uPFK-2
(ubiquitous)
iPFK-2
(inducible)
AMPK, PKA, Akt, PKC,
Smad, RSK, p38-MK2
Estrogens, adenosine, LPS
p53, S-glutathionylation,
demethylation
PFKFB4 3p21.31 4.1 (rat testis)
0.9 (human
testis)
tPFK-2 (testis) HIF-1α, P-PPARγ,
testosterone
p53
TIGAR C12orf5 12p13.32 Only
phosphatase
Not described p53, CREB, HIF-1α, SP1
Information regarding gene name, chromosomal location, isoenzymes, enzymatic activity, and regulation of the glycolytic enzymes acting on Fru-6-P/Fru-1,6-P2 substrate cycle is
shown. Positive and negative regulators are written in green and red, respectively. *Same chromosomal region, different locus.
domain of p85α and promotes the activation of PI3K and Akt,
leading to increased PFKFB2 activity, Fru-2,6-P2 synthesis and
PFK1 activation, which in turn promote cell proliferation and
tumorigenesis (61).
Fructose 1,6-Bisphosphatase (FBPase1)
FBPase1, a rate-limiting enzyme that catalyzes the opposite
reaction to that of PFK1 in the Fru-6-P/Fru-1,6-P2 cycle, exists
as two isoenzymes in mammals: FBPase1 and FBPase2. Both
isozymes are inhibited by Fru-2,6-P2 synergistically with AMP
(41, 62, 63) (Figure 1). FBPase1 can be phosphorylated by
different kinases, but this leads to non-significant catalytic effects
(41). FBPase1 is ubiquitously expressed and has been reported to
be lost in several human cancers (64). FBPase1 overexpression
suppresses cancer cell growth (65) and its loss correlates with
advanced tumor stage and poor prognosis (66). Snail can repress
FBPase1 in breast cancer cells (67), thus tightly controlling
glucose flux through the PPP, by suppressing both PFK-P
and FBPase1. FBPase1 and PFK-L directly interact forming
multienzyme complexes that can modulate their activities
(53). By contrast, FBPase2 is restricted to muscle cells and
participates in the synthesis of glycogen from carbohydrate
precursors (62).
FIGURE 2 | Structure of β-Fructose 2,6-bisphosphate.
6-Phosphofructo-2-Kinase/fructose
2,6-Bisphosphatase (PFK-2/FBPase-2)
Isoenzymes
Fru-2,6-P2 (Figure 2), a powerful allosteric modulator of the
Fru-6-P/Fru-1,6-P2 substrate cycle, was discovered in 1980 when
its concentration was observed greatly increased in hepatocytes
upon incubation with glucose and disappeared in the presence
of glucagon, providing a refined regulatory mechanism between
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glycolysis and gluconeogenesis (41, 68–71) (Figure 2). Fru-2,6-
P2 has a dual function, increasing the affinity of PFK1 for Fru-
6-P and releasing the enzyme from ATP-mediated inhibition.
It also synergistically increases the affinity of PFK1 for AMP,
a positive allosteric effector of the enzyme. By contrast, both
Fru-2,6-P2 and AMP inhibit FBPase1 (41, 68–71). Furthermore,
Fru-2,6-P2 stabilizes PFK1 (68) and promotes its association
into tetramers and higher oligomers with enhanced activity
(72). Therefore, changes in the concentration of this metabolite
regulate the activities of PFK1 and FBPase1, thereby conferring a
key role to Fru-2,6-P2 in the regulation of the Fru-6-P/Fru-1,6-
P2 substrate cycle and the intensity and direction of glycolysis
and gluconeogenesis (Figure 1). Since Fru-2,6-P2 does not take
part as an intermediary in any metabolic interconversion, and
given its lability in acid extracts used to measure phosphoric acid
esters in tissues, this metabolite managed to escape discovery
until 1980 (41, 70). Fru-2,6-P2 has been shown to carry out a
leading function in regulating glycolysis in other eukaryotic cells
(41, 68, 69).
Fru-2,6-P2 concentration is significantly higher in tumor
cells than in normal cells (56, 73, 74) and is regulated by
different bifunctional isoenzymes called 6-phosphofructo-
2-kinases/fructose 2,6-bisphosphatases (PFK-2/FBPase-2),
which catalyze the synthesis and degradation of this
metabolite (68–71, 75). The balance between the activity
of 6-phosphofructo-2-kinase (PFK-2), which synthesizes
Fru-2,6-P2 from Fru-6-P and ATP, and that of fructose 2,6-
bisphosphatase (FBPase-2), which hydrolyzes Fru-2,6-P2 into
Fru-6-P and inorganic phosphate, ultimately determines the
concentration of this metabolite (Figure 1). PFK-2/FBPase-2 is
one of the few homodimeric bifunctional enzymes, composed
of two 55-kDa subunits. Each monomer presents both kinase
and bisphosphatase domains in the same polypeptide chain,
with the kinase domain at the N-terminal end of the protein and
the bisphosphatase domain at the C-terminal (68–71, 75, 76)
(Figure 3). The amino acids located near the N- and C-
terminal ends of the PFK-2/FBPase2 isoenzymes protein are
responsible for its post-translational regulation as they can
be phosphorylated by different protein kinases. The protein
is derived from the fusion of two genes that express a kinase
domain, evolutionarily related to the family of proteins that
link mononucleotides, and a bisphosphatase domain, which is
related to the family of phosphoglycerate phosphatases and acid
phosphatases (75–77). The regulatory function of Fru-2,6-P2 in
carbohydrate metabolism implies that the modulation of Fru-
2,6-P2 synthesis and degradation must be very well compensated
to adapt Fru-2,6-P2 concentration to the needs of the cell. The
degree of complexity involved in regulating Fru-2,6-P2 levels
in each tissue and physiological condition is reflected by the
existence of different PFK-2/FBPase-2 isoenzymes that are
capable of adapting to different conditions (75, 76, 78). These
isoenzymes, encoded by four genes (PFKFB1-PFKFB4), display
variances in their kinetic properties and distribution, as well as
in their responses to allosteric, hormonal, and growth factors
(75, 76). The PFKFB1 gene encodes the isoforms that were
originally identified in the liver, muscle and fetal tissue, while the
PFKFB2 gene encodes the isoenzyme occurring in the heart and
FIGURE 3 | Domain organization of PFK-2/FBPase-2 isoenzymes. The
N-terminal PFK-2 domain is shown in yellow and the C-terminal FBPase-2
domain is in purple. Regulatory regions with residues susceptible of
phosphorylation by different protein kinases are shown in blue.
kidney and in some cancer cells. The PFKFB3 gene encodes the
isoforms present in the brain, placenta and adipose tissue, and is
the most expressed PFKFB gene in proliferating and cancer cells.
Finally, the PFKFB4 gene encodes the isoenzyme occurring in the
testis, although it has also been found in several types of tumor
cells (Table 1).
PFKFB1
The PFKFB1 gene was cloned from rat and human liver (71, 79,
80) and is composed of 60,944 bp. It contains 17 exons under
the control of different promoters and gives rise to three different
transcripts, mRNAs L (liver), M (muscle), and FL (fetal) (68, 70,
75, 81). The muscle and fetal transcripts have the same sequence
as that of the liver, except for the exon encoding the N-terminal
end containing the S32 residue, that can be phosphorylated by the
cAMP-dependent protein kinase (PKA) in response to glucagon
and dephosphorylated by protein phosphatase 2A (PP2A),
activating the bisphosphatase and inhibiting the kinase activities
of the liver isoenzyme, respectively (68, 70, 82) (Figure 3). The
FL mRNA variant, present in several rat-derived cell lines and
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proliferating tissues, contains two non-coding exons (1aF and
1bF) (83). Although the liver, muscle and fetal isoenzymes
come from the same gene, they are regulated differently, since
glucagon induces glucose synthesis in the liver but not in other
tissues. PFKFB1 has not been found to be overexpressed in
cancer cells.
PFKFB2
The human PFKFB2 gene was cloned from human heart and
it contains 15 exons spanning 27,961 bp. This gene generates
nine transcripts, four of which encode full-length proteins, two
encode truncated proteins and the other three contain an open
reading frame without producing any protein (84). PFKFB2 is a
homodimeric protein, with isoform A being a 58-kDa protein
containing 505 amino acids and isoform B a 54-kDa protein
containing 471 amino acids. The sequence of the catalytic site
is preserved, but those of the N- and C-terminal regions exhibit
more variances (75, 76, 84, 85). PFKFB2 is mainly expressed
in the heart, being also located in other tissues, but in lesser
proportion (76, 86). Moreover, it is expressed in cancer cells from
different origins (76, 86, 87).
PFKFB2 can undergo multisite phosphorylation, integrating
signals from many pathways (Figure 3). The C-terminal domain
residues S29, S466, T475 and S483 can be phosphorylated by
protein kinases such as 3-phosphoinositide-dependent kinase-
1 (PDPK-1), AMP-activated protein kinase (AMPK), PKA,
protein kinase B (PKB; also known as Akt), mitogen-activated
protein kinase 1 (MAPK-1), and p70 ribosomal S6 kinase
(S6K1). PFKFB2 phosphorylation at three conserved residues
(S466, T475, and S483) results in the activation of the enzyme,
decreasing its Km for Fru-6-P and increasing the Vmax of PFK-
2 activity (75). PFK-2 activity, however, varies depending on the
kinase that activates it (75, 88). Moreover, it has been proposed
that the 14-3-3 proteins, which promote cell survival (89), bind to
PFKFB2 when it is phosphorylated at S483 by Akt in response to
insulin and IGF-1 or when transfected with active forms of Akt,
mediating growth factors-induced glycolysis (90). Oncogenic
BRAF V600E has also been found to activate p90 ribosomal
S6 kinase (RSK), which phosphorylates and activates PFKFB2,
that then binds to 14-3-3 to promote glycolysis and melanoma
cell growth (91). Furthermore, amino acids increase Fru-2,6-P2
synthesis and glycolysis in cardiomyocytes and cancer cell lines
by PI3K and Akt-mediated phosphorylation of PFKFB2 at S483
(92).Moreover, EGFR activation induces PFK-P phosphorylation
(Y64), which binds to the N-terminal SH2 domain of p85α
and promotes Akt-dependent PFKFB2 phosphorylation (S483),
glycolysis, cell proliferation and brain tumorigenesis (61).
Adrenalin promotes PFKFB2 phosphorylation by PKA at S466
and S483, while AMPK activation during ischemia or hypoxia
induces PFKFB2 phosphorylation at S466, which increases Fru-
2,6-P2 levels and stimulates glycolysis (75, 88). PFKFB2 is also
a substrate of PKC, which phosphorylates S84, S466, and T475
residues (75, 93) (Figure 3). Several studies have reported that
HIF-1α can regulate PFKFB2 expression in vivo but this appears
to be cell-specific (86). Citrate, whose concentration is increased
by the oxidation of fatty acids and ketone bodies, competitively
blocks Fru-6-P binding, down-regulating PFKFB2 expression
and glycolysis through the “glucose-sparing effect” (85).
PFKFB2 is one of the genes increased in lymphoblasts
from glucocorticoid (GC)-treated children suffering from acute
lymphoblastic leukemia (94). Surprisingly, overexpression of
the two PFKFB2 splice variants seems to have little effect on
lactate and ATP production, two metabolites that are reduced
after GC treatment, and cell survival, suggesting that this gene
is not an essential regulator of the anti-leukemic effects of
GC (95). The androgen receptor (AR) is a key regulator of
prostate growth, promoting glycolysis and anabolic metabolism,
and the principal drug target for the treatment of prostate
cancer (96). One of the mechanisms behind this phenotype
is the transcriptional upregulation of PFKFB2, possibly under
the control of the AR-CAMKII-AMPK signaling pathway (96).
Androgens have been shown to stimulate glycolysis for de
novo lipid synthesis. Androgens promote transcriptional up-
regulation of de novo, mediated by binding of ligand-activated
AR to its promoter, and phosphorylation of PFKFB2 generated
by the PI3K/Akt signaling pathway. Moreover, blocking PFKFB2
expression with siRNA or inhibiting PFK-2 activity with
LY294002 (PI3K inhibitor) has been observed to reduce glucose
uptake and lipogenesis, suggesting that the induction of de novo
lipid synthesis by androgens requires the transcriptional up-
regulation of PFKFB2 (97). PFKFB2 expression is also enhanced
in human gastric malignant tumors, being associated with
increased levels of HIF-1α dependent genes, vascular endothelial
growth factor (VEGF) and Glut1, indicating that HIF-1α could
be responsible for the induction of PFKFB2 expression (87).
In hepatocellular carcinoma, high expression of metastasis-
associated in colon cancer protein 1 (MACC1), a key regulator
of the hepatocyte growth factor (HGF)/c-Met pathway, has
been noted to correlate with the high expression of PFKFB2,
this correlation being associated to TNM stage (classification
of malignant tumors), overall survival and Edmondson-Steier
classification (98). Furthermore, MAPK-activated RSK, which
directly phosphorylates PFKFB2, is required to maintain
glycolytic metabolism in BRAF-mutated melanoma cells. RSK
inhibition reduces PFKFB2 activity and glycolytic flux, suggesting
an important role for RSK in BRAF-mediated metabolic rewiring
(91).
Another observation highlighting the importance of PFKFB2
in metabolic reprogramming is its contribution to osteosarcoma
development. Slit guidance ligand 2 (SLIT2) binds to round
about guidance receptor 1 (ROBO1) and plays important roles
in various physiological and pathological conditions, such as
axon guidance, organ development, and angiogenesis (99). The
SLIT2/ROBO1 axis promotes proliferation, inhibits apoptosis
and contributes to the Warburg effect in osteosarcoma cells via
activation of the SRC/ERK/c-MYC/PFKFB2 pathway (99).
PFKFB2 expression has also been linked to the regulation
of non-coding RNAs. In ovarian cancer, the long non-
coding RNA LINC00092 has been identified as a nodal driver
of CAF-mediated metastasis. The pro-metastatic properties
of CAFs have been linked to the elevated expression of
both the chemokine CXCL14 and PFKFB2, correlating with
poor prognosis. Mechanistic studies have demonstrated that
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LINC00092 binds PFKFB2, thereby promoting metastasis by
inducing a glycolytic phenotype in these tumors and sustaining
the local supportive function of CAFs (100). Similarly, the
long non-coding RNA UCA1/miR-182 has been observed to
be a nodal driver of metastasis in glioma that is mediated by
glioblastoma-associated stromal cells (GASCs) and the GASC-
secreted chemokine CXCL14. In clinical specimens, CXCL14
upregulation in GASCs cells was seen to correlate with
poor prognosis. Interestingly, GASCs expressing high levels
of CXCL14 have been shown to upregulate lncRNA UCA1
and downregulate miR-182, with miR-182 directly binding to
PFKFB2 to modulate CXCL14 secretion, glycolysis, and the
invasion of glioma cells (101).
PFKFB2 has also important roles in the physiology of human
CD3+ T cells. Treatment of activated human CD3+ T cells with
the proinflammatory chemokine CCL5 induces the activation of
AMPK and PFKFB2 phosphorylation and activation, promoting
glycolytic flux and suggesting that both glycolysis and AMPK
signaling are required for efficient T cell activation in response
to CCL5 (102).
PFKFB3
The PFKFB3 gene was cloned from a cDNA library of fetal
brain and has been found expressed in all the tissues studied
(103–107). It spans 109,770 bp and is composed of 19 exons.
The variable C-terminal domain can undergo alternative splicing
to produce six different isoforms. The two main isoforms are
generated by alternative splicing of exon 15 and differ in
their C-terminal sequence, the 4,553 bp mRNA variant initially
named as ubiquitous PFK-2 (uPFK-2) (107) and the 4,226 bp
mRNA inducible PFK-2 (iPFK-2) variant (106). Four additional
splice variants have also been described (108). As many
proto-oncogenes and pro-inflammatory cytokines, PFKFB3 has
multiple copies of the AUUUA sequence in the 3′UTR of its
mRNA, which confer instability and enhanced translational
activity (106). It has been found that miR-26b and miR-206
interact with the 3′UTR of the PFKFB3 mRNA, decreasing
glycolysis in osteosarcoma and breast cancer cells, respectively
(109, 110).
PFKFB3 gene expression is induced by different stimuli,
such as hypoxia (31, 111, 112), progestin (104, 113), estrogens
(114) and stress stimuli (115), through the interactions of HIF-
1α, the progesterone receptor (PR), estrogen receptor (ER),
and the serum response factor (SRF). These factors bind to
specific sequences in PFKFB3 promoter which are the consensus
hypoxia response element (HRE), the progesterone response
element (PRE), estrogen response element (ERE), and the serum
response element (SRE), respectively. PFKFB3 expression can
also be stimulated by growth factors such as insulin (73),
pro-inflammatory molecules (106) such as interleukin-6 (IL-
6) (116, 117), lipopolysaccharide (LPS) and adenosine (118),
mitogenic lectins such as concanavalin A (ConA) (119) and
phytohemagglutinin (PHA) (120), and the transforming growth
factor beta 1 (TGF-β1) (121).
PFKFB3 gene expresses an isoenzyme that has high kinase
and low bisphosphatase activity (K/B = 710), favoring the
net synthesis of Fru-2,6-P2 and eliciting high concentrations
of this metabolite in proliferating and tumor cells (122). The
presence of a serine instead of an arginine at position 302 in the
bisphosphatase active site gives place to the low bisphosphatase
activity (123).
Different protein kinases, such as AMPK (124, 125),
RSK (113), MK2 (115), PKA, PKB (119), and PKC (125)
regulate the PFKFB3 isoenzyme by covalent modification of
its C-terminal domain (Figure 3). PI3K/Akt also controls the
PFKFB3 isoenzyme downstream of growth factors signaling (119,
126, 127). Phosphorylated PFKFB3 has increased Vmax of its
kinase activity and decreased Km for fructose-6-P (119, 124).
ROS-mediated S-glutathionylation (128) or demethylation (129)
also regulate PFKFB3 in cancer cells, decreasing its catalytic
activity and redirecting the glycolytic flux to the PPP, increasing
NADPH and decreasing ROS levels. Similarly, cell damage-
mediated induction of p53 stimulates nucleotide biosynthesis
by inhibiting PFKFB3 expression and enhancing the flux of
glucose through the PPP to increase nucleotide production,
which promotes DNA repair and cell survival (130) (Figure 4).
The PFKFB3 isoenzyme can also be regulated through the
ubiquitin-proteasome system (131), as it contains a KEN box
that can be ubiquitinated by the E3 ubiquitin ligase of the
anaphase-promoting complex (APC/C), which is activated by
Cdh1, in a similar way to that of other proteins in the cell
cycle. The proliferative response depends on the reduced activity
of APC/C-Cdh1 to activate proliferation and glycolysis (132).
PFKFB3 silencing prevents cell cycle progression, illustrating that
this isoenzyme is essential for cell division (133). The tumor
suppressor PTEN promotes APC/C-Cdh1 activity (127, 134)
and cells from mice that overexpress PTEN show APC/C-Cdh1-
mediated degradation of PFKFB3 and glutaminase, resulting
in a decrease of glycolysis and proliferation, and an increase
in resistance to oncogenic transformation (127). PFKFB3
isoenzyme levels have also been shown to increase in proliferating
cells through the activation of cyclin D and E2F1, two
downstream effectors of the PI3K-Akt-mTOR pathway (126),
localizing in the nucleus and regulating proliferation through
cyclin-dependent kinases (135). The nuclear targeting of PFKFB3
has been shown to increase cyclin-dependent kinase 1 (CDK1)
expression among other cell cycle proteins. In particular, Fru-
2,6-P2 stimulates the phosphorylation of the Cip/Kip protein
p27 mediated by CDK1, which in turn elicits p27 ubiquitination
and proteasomal degradation (136). PFKFB3 also interacts with
CDK4, inhibiting its degradation via the ubiquitin proteasome
pathway to promote cell cycle progression (137).
PFKFB3 expression is induced by endotoxin in human
macrophages (106, 124). Macrophage Toll-4 receptor agonists
cooperate with adenosine to increase glycolysis by heightening
PFKFB3 gene expression and Fru-2,6-P2 synthesis, which
increases glycolysis and favors ATP synthesis, developing the
long-term defensive and reparative functions of macrophages
(118). Macrophage glycolysis and pro-inflammatory activation
mainly depend on HIF-1α and its effects on glucose uptake
and the expression of hexokinase-II (HK-2) and PFKFB3
(138) (Figure 4). These findings indicate that hypoxia enhances
glycolytic flux in macrophages through HIF-1α and PFKFB3
proportionally to the upregulation of pro-inflammatory activities
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FIGURE 4 | Molecular mechanisms of the Warburg effect. Hypoxia stabilizes HIF-1α, which transactivates most of the glycolytic genes, such as HK-II and PFKFBs, as
well as PDK1, which in turn inhibits PDH, that catalyzes the conversion of pyruvate to Ac-CoA. PDH inhibition blocks the entry of pyruvate into the TCA, promoting the
oxidation of pyruvate to lactate. Lactate is then excreted through the MCT transporters, which expression is also increased by HIF-1α. p53 inhibits the glycolytic genes
PFKFB3, PFKFB4, and PGAM and the lactate transporter MCT1, and induces TIGAR, reducing the glycolytic flux. This results in increased flux of the pentose
phosphate shunt to produce NADPH and ribose-5P. Moreover, p53 stimulates respiration by inducing SCO2, a component of cytochrome c oxidase (COX). In tumors,
limited access to oxygen and mutations in the p53 gene drive to increased glycolysis, a phenomenon named as the Warburg effect.
in these cells (138). These in vivo observations suggest that HIF-
1α antagonists or PFKFB3 inhibitors could be used to alleviate
inflammatory diseases. Furthermore, cytosolic viral recognition
by secondary interferon signaling has been demonstrated to
upregulate glycolysis preferentially in macrophages through
PFKFB3 induction, promoting the extrinsic antiviral capacity of
macrophages and being a crucial component of innate antiviral
immunity (139).
PFKFB3 is constitutively overexpressed in different cancer cell
lines and in several human leukemias and solid tumors (140,
141), including ovarian and thyroid carcinomas (142), colon
adenocarcinoma, breast cancer, gastric tumors and pancreatic
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cancer (73, 87, 111, 113, 143), and has been associated with
lymph node metastasis and the TNM stage (143). PFKFB3 can
also represent a biomarker and an anti-neoplastic target in gastric
cancer (144). Furthermore, PFKFB3 expression is required for
cell growth and increasedmetabolic activity inmyeloproliferative
neoplasms expressing the oncogenic JAK2V617F kinase, which is
a very common mutation in these malignancies. JAK2V617F and
active STAT5 overexpress PFKFB3 and PFKFB3 silencing reduces
cell growth under normoxic and hypoxic conditions and prevents
tumor formation (145). In chronic myeloid leukemia (CML),
PFKFB3 has been found to be strongly associated with resistance
to the BCR-ABL tyrosine kinase inhibitors. PFKFB3 silencing
or pharmacological inhibition of its kinase activity enhances the
sensitivity of CML cells to these inhibitors (146). In acutemyeloid
leukemia (AML), mTOR-mediated up-regulation of PFKFB3 is
essential for cell survival, as mTORC1 up-regulates PFKFB3 in
a HIF1α-dependent manner, and PFKFB3 silencing suppresses
glycolysis and cell proliferation and activates apoptosis (147).
In malignant human colon tumors, PFKFB3 overexpression
and phosphorylation of its S461 residue (P-PFKFB3 S461) has
been observed (148). The cytokine IL-6 increases glycolysis by
inducing PFKFB3 expression through STAT3 activation (116),
suggesting a functional role of PFKFB3 in chronic inflammation
and in the development of colorectal cancer (117). Similar results
have been reported in TGF-β1-induced lung fibrosis, in which
PFKFB3 inhibition attenuates prefibrotic phenotypes and blocks
the differentiation of lung fibroblasts (149). Furthermore, we have
shown that TGF-β1 overexpresses PFKFB3 mRNA and protein
in glioblastoma cells through the activation of the Smad, p38
MAPK and PI3K/Akt signaling pathways. Inhibiting PFKFB3
expression or activity significantly suppressed the ability of T98G
cells to form colonies, which is one of the hallmarks of cell
transformation (121).
High-grade astrocytomas also contain increased PFKFB3
protein levels (150). The expression of the PFKFB splice variant
UBI2K4 prevents tumor cell growth, acting as a tumor suppressor
in astrocytic tumors (151). Besides, loss of heterozygosity in
10p14-p15, which leads to the allelic deletion of UBI2K4, has
been detected in 55% of glioblastomas and is associated with poor
prognosis (152).
PFKFB3 has also a key role in the interaction between
cancer cells and other cells in the TME. Endothelial cells (ECs)
depend on glycolysis more than on oxidative phosphorylation
for ATP synthesis and loss of PFKFB3 in ECs impairs vessel
formation (52). Inhibition of glycolysis by silencing PFKFB3
expression or pharmacologically blocking its kinase activity
has been observed to inhibit pathological angiogenesis, such
as ocular and inflammatory disease, without causing systemic
effects (153). Recently, an article reported that targeting
PFKFB3 in ECs significantly impeded metastasis by normalizing
tumor vessels and improved the delivery and efficacy of
chemotherapy (154). Nuclear factor (erythroid-derived 2)-like 2
(Nrf2) regulates endothelial glycolysis and proliferation through
the transcriptional regulation of PFKFB3, VEGFA, FOXO1, and
MYC (155), with a positive correlation occurring between Nrf2,
HIF-1α, and PFKFB3 expression in breast cancer cells, and cancer
patients with high PFKFB3 expression showing poorer overall
survival (156).
PFKFB3 expression is also linked to hepatocellular carcinoma
(HCC) growth. PFKFB3 overexpression has been associated
with a large tumor size and poor survival in patients, while
PFKFB3 knockdown inhibits HCC growth by reducing glucose
consumption and impeding DNA repair, which leads to cell
cycle arrest at the G2/M phase and apoptosis. Silencing PFKFB3
expression decreases Akt phosphorylation and reduces the
expression of ERCC1, a protein involved in DNA repair (157).
The combination of aspirin and sorafenib has been shown
to perform a synergistic effect against liver cancer. PFKFB3
overexpression, associated with high glycolytic flux, is frequently
observed with sorafenib resistance, which can be overcome by
aspirin. By inhibiting PFKFB3, sorafenib plus aspirin induce
apoptosis in tumors without eliciting weight loss, hepatotoxicity
and inflammation, suggesting that their combination may be an
effective treatment for HCC (158).
A large number of studies have reported that increased
PFKFB3 expression promotes proliferation and carcinogenesis,
indicating that its inhibition could be crucial for treating
inflammation and cancer. Indeed, siRNA suppression of PFKFB3
has been reported to reduce cancer cell viability (159, 160) while
small molecule inhibitors of the PFKFB3 isoenzyme have been
developed (161).
PFKFB4
PFKFB4, firstly cloned from rat (162) and human testis (163), is
a 44,332 bp gene composed of 14 exons. Several splice variants
have been reported, with the PFK-2 core domain being conserved
among all of them (162, 164). The PFKFB4 gene encodes an
isoenzyme that is expressed in the testis under the regulation of
testosterone (165, 166). Moreover, it has been demonstrated that
PFKFB4 mRNA and protein levels are regulated by hypoxia and
glucose levels in different cancer cell lines from the prostate, liver,
colon, bladder, stomach and pancreas (86, 87, 167–171). PFKFB4
is a prognostic marker in invasive bladder cancer (172), where
its expression is activated by HIF-1α (171) (Figure 4). In hepatic
cancer cell lines, sulforaphane-induced apoptosis was shown to
decrease PFKFB4 protein expression and glucose consumption
whereas HIF-1α induced PFKFB4 expression under hypoxic
conditions (173). PFKFB4 expression is also controlled by heme-
oxygenase-2 in HepG2 cancer cells (174). In HCC, upregulated
Peroxisome proliferator-activating receptor γ (PPARγ) induces
PFKFB4 expression through the transcriptional activity of its
promoter, regulating glycolysis and cell proliferation (175). High
PFKFB4 mRNA and protein expression have been described in
three different glioblastoma stem-like cell lines, with shRNA-
mediated knockdown of PFKFB4 promoting apoptosis (176)
and no phenotypic effect occurring in PFKFB4-silenced normal
neural stem cells. Furthermore, HIF1α-induced PFKFB4 mRNA
expression correlates with glioma tumor grade (176).
PFKFB4 is required to balance glycolytic activity and
antioxidant production to maintain the cellular redox balance
in prostate cancer cells (169). PFKFB4 mRNA expression has
been found to be greater in metastatic prostate cancer cells than
in primary tumors. PFKFB4 silencing selectively increases Fru-
2,6-P2 concentration in prostate cancer cells, suggesting that
it mainly functions as a fructose-2,6-bisphosphatase in these
particular cells. The increase in Fru-2,6-P2 levels should direct
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glucose 6-phosphate toward the glycolytic pathway, thereby
reducing the activity of the PPP. This would explain why prostate
cancer cells show lower NADPH and glutathione levels after
PFKFB4 silencing, which results in enhanced oxidative stress
and cell death (169). Furthermore, p53 decreases PFKFB4 gene
expression by binding to its promoter to mediate transcriptional
repression via histone deacetylases. PFKFB4 depletion also
attenuates biosynthetic activity and induced ROS accumulation
and cell death in the absence of p53 (177).
In a study investigating the differences in glucose metabolism
between two forms of prostate cancer, small cell neuroendocrine
carcinoma (SCNC) was found to be more glycolytic than
adenocarcinoma, CD44 being a key regulator of glucose
metabolism. PFKFB4 expression in benign prostate tissue was
lower than that in the adenocarcinoma, and significantly higher
in SCNC. CD44 ablation in SCNC cells reduced both mRNA
and protein levels of PFKFB4 (178). Thus, CD44 can modulate
the aggressive phenotype of prostate cancer cells by increasing
PFKFB4 expression (179).
PFKFB4 can also regulate autophagy by influencing the redox
balance. In PC3 prostate cancer cells, PFKFB4 inhibition was
observed to cause p62 accumulation, which is usually associated
with the inhibition of autophagy. However, the autophagic flux
was increased in these cells. The combination of antioxidants
and PFKFB4 inhibition prevented p62 accumulation, which
was instead mediated by Nrf2, thus avoiding autophagy.
Hence, PFKFB4 expression is required for appropriate ROS
detoxification in these cells (180). It was recently found
that epithelial and endothelial tyrosine kinase interacts with
PFKFB4 modulating chemoresistance of small-cell lung cancer
by regulating autophagy (181).
Solid malignant tumors of the breast present a higher
PFKFB4 expression compared to non-malignant tissue. In
several breast cancer cell lines, PFKFB4 expression increased
upon exposure to hypoxia (87). PFKFB4 was recently shown
to act as a protein kinase phosphorylating the oncogenic
steroid receptor coactivator-3 (SRC-3) and enhancing its
transcriptional activity to drive breast cancer (182). PFKFB4
suppression or ectopic expression of a phosphorylation-
deficient S857A mutant of SRC-3 abolished SRC-3-mediated
transcription. Mechanistically, SRC-3 phosphorylation increases
its binding with the ATF4 transcription factor by stabilizing
the recruitment of SRC-3 and ATF4 to target gene promoters.
Functionally, PFKFB4-induced SRC-3 activation directs the
glucose flux toward the PPP and the synthesis of purines by
transcriptionally upregulating the expression of transketolase.
PFKFB4 or SRC-3 silencing inhibits breast tumor growth and
metastasis (182).
Apart from the importance of PFKFB4 in regulating cancer
cell glycolysis, its expression also determines the metabolic
adaptation of non-tumor cells. In mitogen-stimulated rat
thymocytes, ConA was shown to induce the expression of
PFKFB3 and PFKFB4 as well as increase glycolysis, cell
proliferation and protein synthesis. This supports a role for
these two proteins in coupling glycolysis to cell proliferation in
lymphoid tissues (119).
TIGAR
The c12orf5 gene was discovered during a computer-based
analysis of microarray data trying to find novel p53-regulated
genes that are activated in response to ionizing radiation (183).
This gene was cloned and characterized, and named as TP53-
Induced Glycolysis and Apoptosis Regulator (TIGAR) (184)
(Figure 4). TIGAR is a target of p53 that becomes rapidly
activated by low levels of stress. The human TIGAR gene
consists of six exons spanning about 38,835 bp, coding for
a unique mRNA transcript variant of 8.2 kb with a 813 bp
coding sequence. TIGAR promoter contains two p53 binding
sites, one upstream of the first exon and the other within the
first intron, the latter being the most efficient (184). TIGAR can
be induced by Nutlin-3, an antagonist of Mdm2 that increases
p53 levels (185), radiotherapy (183, 186), glutamine (29),
chemotherapy (187), UV light (187), TNFα, and radiotherapy
mimetics (188) or by the Akt signaling pathway in response
to the metabolic stress caused by PFKFB3 knockdown (189).
TIGAR expression can also be regulated in a p53 independent
manner (186, 189) by linking the CRE-binding protein (CREB)
to the TIGAR promoter (190). Another transcription factor, the
specificity protein 1 (SP1), can bind to TIGAR promoter and
is considered important for its basal activity (191). TIGAR can
be induced in response to hypoxia in myocytes (192) and some
studies have identified HIF-1α as a regulator of cytochrome
C-oxidase-2 (SCO2) and TIGAR gene expression in response to
hypoxia (193). SCO2, a metallochaperone that is involved in the
biogenesis of cytochrome C oxidase subunit II, participates in the
mitochondrial chain, it is also induced by p53 and its blockage
leads to the glycolytic phenotype (194).
The human TIGAR protein is composed of 270 amino
acids and has a molecular weight of 30 kDa. It contains a
bisphosphatase active center in which two histidine residues,
H11 and H198, and one glutamic acid, E102, are essential
for its activity (184). TIGAR contains a catalytic domain
similar to the histidine phosphatase superfamily of proteins
with a histidine forming a transient phosphoenzyme during
catalysis (195). This domain shares similarity with those of
the phosphoglycerate mutase (PGAM) family of enzymes and
with the bisphosphatase domain of PFK-2/FBPase-2 isoenzymes
(196). TIGAR bisphosphatase activity hydrolyzes Fru-2,6-P2 into
Fru-6-P, which can then enter in the PPP to synthesize NADPH
and ribose-5-phosphate, thus reducing ROS and producing
nucleotide precursors that are essential for biosynthesis, DNA
repair and cell proliferation (184) (Figure 4). As TIGAR has no
kinase domain, it behaves as a kinase-deficient PFKFB isoform.
Thus, cells overexpressing FBPase-2 show similar enhanced PPP
flux and resistance to oxidative stress (197). The FBPase catalytic
activity of TIGAR is several orders of magnitude lower than
that of the FBPase-2 component of PFK-2/FBPase-2 isoenzymes,
pointing out that Fru-2,6-P2 could not be its main physiological
substrate (198).
TIGAR mRNA is expressed in all the tissues in which it
has been analyzed to date and is overexpressed in several
cancer cells. It localizes mainly in the cytoplasm, but has been
observed to relocalize to the outer mitochondrial membrane
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under hypoxic conditions to form complexes with HK-2, limiting
ROS production (199).
TIGAR has also been linked to autophagy. For example,
TIGAR overexpression and reduced ROS levels have been
observed alongside suppressed autophagy in cells exposed to
stress conditions, and TIGAR suppression induced autophagy
that subsequently mediates apoptosis by restraining ROS levels
(200). The relationship between autophagy and apoptosis is
regulated distinctively according to the stimulus and cell type.
Thus, treatment of neuroblastoma cells with D-galactose induces
necroptosis and autophagy, as reflected in the upregulation of
BMF, BNIP3, ATG5, and TIGAR, without affecting the expression
of the genes associated with apoptosis (201). Decreased mRNA
levels of TIGAR and reduced levels of the damage-regulated
autophagy modulator (DRAM) have been reported in HepG2
cells exposed to high oxidative stress or nutrient starvation
(202). Upon disruption of the homeostasis balance of the
cell, TIGAR is activated and provides protection through its
antioxidant properties rather than by inhibiting autophagy, while
other transcriptionally activated targets, such as DRAM, enhance
autophagy (203). Some studies have proposed that p53 regulates
stress-induced autophagy by balancing TIGAR and DRAM,
which have opposite effects (204, 205).
Like the PFKFB isoenzymes, TIGAR can also play a role
in cancer. The function of TIGAR in a specific cell type
depends on the metabolic state of the cell and PFKFBs activities
that determine Fru-2,6-P2 concentration and glycolytic flux.
TIGAR activity could limit glycolysis and produce antioxidant
molecules and precursors for nucleotide synthesis, thereby
limiting cancer development. However, TIGAR overexpression
can also promote the growth of tumor cells with high ROS
levels. TIGAR has been reported not be necessary for normal
growth and development in mice, but plays an important
function in intestinal regeneration. The lack of TIGAR causes
growth defects which are recovered by ROS scavengers and
nucleosides (206). Besides, TIGAR deficiency has been reported
to reduce tumor growth and improve survival in a mouse
intestinal adenoma model, while elevated TIGAR expression
supported cancer progression (206). TIGAR expression is
increased in human breast, gastric and lung cancer, inversely
correlating with p53 expression levels (207–209). Furthermore,
TIGAR downregulation inhibits growth in several cancer cell
lines (184). In a model of nasopharyngeal cancer, 1-(3-C-
ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), an RNA-
nucleoside anti-metabolite with potent anticancer activity, was
shown to downregulate TIGAR and deplete NADPH. TIGAR
overexpression was able to recover the growth inhibition
induced by ECyd (210). In the same model, c-Met protein
kinase maintained TIGAR expression, whereas c-Met silencing
significantly decreased TIGAR expression and subsequently
depleted intracellular NADPH, which lead to cell death (211).
TIGAR silencing induces also apoptosis and autophagy in
HepG2 cells (212), while RNAi-mediated knockdown of citrate
synthase in human cervical carcinoma cells accelerates cancer
cell metastasis and proliferation deregulating the p53/TIGAR
pathway (213). In HeLa cervical carcinoma cells, TIGAR can
be induced in an Akt-dependent manner in response to the
inhibition of glycolysis. PFKFB3 depletion by RNAi increases
ROS levels and decreases cell viability, this effect being highly
exacerbated when TIGAR is also inhibited. However, TIGAR
inhibition alone does not have an impact on HeLa cell survival
(189). Furthermore, some studies have reported that TIGAR
regulates the cell cycle by de-phosphorylating the retinoblastoma
protein (RB) and stabilizing RB-E2F1 complex, thus delaying
entry into the S phase (187, 214).
In multiple myeloma cells, inhibition of MUC1-C
oncoprotein increases ROS levels and downregulates TIGAR
expression, resulting in decreased NADPH and glutathione
levels and promoting ROS-mediated apoptosis/necrosis (215).
Sensitivity to fludarabine and p53-mediated TIGAR induction
has been described in chronic lymphocytic leukemia. The
sensitivity to fludarabine varied despite all patients presented
wild-type p53 (216). Glioblastoma cells overexpress TIGAR
which reduces cell death induced by restricting glucose and
oxygen (217). These results indicate the potential therapeutic
use of TIGAR as an antitumoral target (186). Similarly,
TIGAR expression was found decreased with a sonodynamic
therapy tested in a neuroblastoma cell model which decreases
cell proliferation, possibly through increased ROS levels
(218). In glioblastoma-derived cell lines, TIGAR abrogation
increased radiation-induced cell destruction, providing a
new therapeutic strategy that could be used to increase cell
death in glial tumors, thus allowing the use of lower doses
of radiotherapy. Gliomas are resistant to radiotherapy and
to TNFα-induced killing. Radiation-induced TNFα increases
radioresistance through nuclear factor κB (NFκB). Thus, the
existence of an ATM-NFκB axis regulating TIGAR indicates its
involvement in the inflammation and resistance to radiomimetics
(188). It was recently reported that TIGAR regulates NF-κB
activation by suppressing phosphorylation and activation of
the upstream IKKβ, which occurs through a direct binding
competition between NEMO and TIGAR for the linear
ubiquitination assembly complex (LUBAC), preventing the
linear ubiquitination of NEMO required for the activation of
IKKβ and other downstream targets. Furthermore, a TIGAR
mutant with impaired phosphatase activity was equally effective
as wild-type TIGAR in inhibiting the linear ubiquitination of
NEMO, IKKβ phosphorylation/activation and NF-κB signaling,
indicating that the effect of TIGAR on NF-κB signaling is due to
a non-enzymatic molecular function, that directly inhibits the E3
ligase activity of LUBAC (219).
In a co-culture system, oxidative stress-induced autophagy
correlated with caveolin-1 (CAV1) downregulation in CAFs and
TIGAR overexpression in adjacent breast cancer cells (Figure 5).
Reduced CAV1 expression in fibroblasts reduces mitochondrial
function and induces glycolysis through HIF-1α and NF-kB
signaling (30). Consequently, autophagic CAFs supply recycled
substrates for the cancer cell metabolism and, also, avoid
cancer cell death by overexpressing TIGAR, thereby conferring
resistance to apoptosis and autophagy (220). Other studies
by the same group have shown that the metabolic coupling
between cancer cells and fibroblasts contribute to tamoxifen
resistance, as CAFs enhanced TIGAR activity in cancer cells,
that protected against tamoxifen-induced apoptosis (221). In
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FIGURE 5 | Metabolic reprogramming in cancer cells. Lactate transport is crucial in the crossed-regulation of metabolism between cancer-associated fibroblasts
(CAFs) and cancer cells. In the fibroblasts close to carcinoma cells, ROS, HIF-1α, and NF-κB induce glycolysis, downregulating CAV1 and upregulating MCT4, which
results in increased lactate secretion in CAFs. Conversely, TIGAR overexpression in carcinoma cells alters their metabolic state, increasing the pentose phosphate
pathway (PPP). Lactate released from CAFs is taken by cancer cells via MCT1 and converted to pyruvate, which can enter the TCA cycle. These cancer cells have
high mitochondrial OXPHOS and low glycolysis, which is associated with high proliferation and low apoptosis rates, resulting in increased tumor growth.
another study, glutamine was described to increase TIGAR
and be needed for CAV1 downregulation in CAFs, decreasing
mediators and markers of autophagy in cancer cells. In this
model, glutamine from autophagic fibroblasts may serve to fuel
cancer cell mitochondrial activity. Thus, a cycle of nutrients
between catabolic stromal cells and anabolic tumor cells has been
suggested to account for the relationship between cells in the
TME (19–21, 28–30, 222). In addition, TIGAR overexpression
has been shown to reprogram carcinoma and stromal cells in
breast cancer (29), as well as to increase oxygen consumption
rates and ATP levels in the presence of glutamine and lactate,
leading to enhanced ATP synthesis. Moreover, when carcinoma
cells overexpress TIGAR in co-cultures with fibroblasts, a
glycolytic phenotype is induced in the fibroblasts, inducing HIF-
1α expression as well as increasing glucose uptake and the
expression of PFKFB3 and lactate dehydrogenase-A. TIGAR
overexpression in carcinoma cells increases tumor growth and
proliferation rates in vivo (29, 30). All these data support
a two-compartment model of tumor metabolism (Figure 5).
The mechanisms by which TIGAR overexpression increases
mitochondrial activity remain unknown to date (29, 217).
Fru-2,6-P2 Metabolism and the Regulation
of Glycolysis and the Pentose Phosphate
Pathway in Cancer Cells
The different PFKFB isoenzymes and TIGAR have important
roles in the TME. The genes encoding these isoenzymes are
commonly overexpressed in tumors and can be induced in
response to cellular stress. These isoenzymes, regulating Fru-2,6-
P2 concentration, have contrary effects on cell metabolism and
different studies have dealt with the cross-regulation of these
enzymes (Figure 4). The contribution of TIGAR to the regulation
of Fru-2,6-P2 levels is expected to vary depending on the
expression levels of the PFKFB1–PFKFB4 isoenzymes. TIGAR
overexpression is associated with decreased survival of patients
with acutemyeloid leukemia (AML) (223) and other tumors (217,
224). Overexpression of PFKFB2-4 has similar outcomes (97, 98,
113, 161, 176). However, crosstalk between these genes must exist
in cancer cells since it has been observed that when TIGAR is
eliminated in leukemia cells expressing high levels of TIGAR,
PFKFB3 expression increase, and when TIGAR is overexpressed
in cells with low levels of TIGAR, PFKFB3 expression decrease
(223).Moreover, we have reported that PFKFB3 silencing inHeLa
cells elevates ROS levels and overexpresses TIGAR through Akt
signaling, preserving against DNA damage and apoptosis (189).
These results indicate that cancer cells sustain high glycolytic flux
in order to fuel biosynthetic pathways under basal conditions.
Nevertheless, if glycolysis is impeded, for example by ROS-
induced S-glutathionylation or demethylation of PFKFB3 (128,
129), PFKFB3 interference, or PFKFB3 inhibitors (189), cancer
cells divert the flow toward the PPP. Cancer cells can also inhibit
glycolysis to decrease ROS in response to DNA damage. In this
respect, following DNA damage, the function of p53 reducing the
mRNA and protein levels of PFKFB3 (130) and PFKFB4 (177) as
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well as the glycolytic flux, while increasing TIGAR expression and
the levels of NADPH and nucleotides through the PPP (184, 186),
enhances DNA repair and cell survival. In this sense, in p53-
deficient cells exposed to UV radiation, glycolysis is not impeded
supporting that p53 is required for this regulatory role (130, 177).
The FBPase catalytic efficiency of TIGAR has been reported to
be several orders of magnitude lower than that of the FBPase-2
activity of PFKFBs (195, 198), thus challenging the concept that
TIGAR acts primarily on Fru-2,6-P2. TIGAR could also exert its
effects by directly increasing flux through the terminal part of
glycolysis, given that it was found to act as the phosphoglycolate-
independent 2,3-bisphosphoglycerate phosphatase (225), with
2,3-bisphosphoglycerate (2,3-BPG), 2-phosphoglycerate (2-PG)
and phosphoenolpyruvate (PEP) being better substrates than
Fru-2,6-P2 (198). These effects could also be enhanced by the
presence of PKM2 in cancer cells, which has low affinity for
PEP and provides a large amount of metabolic precursors for
biosynthesis (14, 226). The concentration of 2,3-BPG in cells is
three orders of magnitude lower than that in erythrocytes (227)
and very little is known about its function, apart from the fact that
it is an essential cofactor for the phosphoglycerate mutase. This
adds a novel layer of complexity to the function of TIGAR that
should be taken into account in future studies.
PFKFB4 expression is essential for prostate and p53-null
colon cancer cell survival, maintaining the balance between
the use of glucose for energy generation and the synthesis of
antioxidants (177). PFKFB4 silencing increases Fru-2,6-P2 levels
in prostate cancer cells, suggesting that it mainly functions as
a fructose-2,6-bisphosphatase in these particular cells, diverting
glucose 6-phosphate toward the PPP (169). By contrast, PFKFB4
that is expressed in other types of transformed cells and
tumors synthesizes Fru-2,6-P2 and is required for the glycolytic
reprogramming of cancer cells (170). Specific analyses of the
enzymatic activity and regulation of PFKFB4 are needed to
characterize its potential role as a FBPase-2 proposed in some
studies (169, 177).
PFKFB4 has been shown to act as a protein kinase of SRC-3
resulting in the upregulation of transketolase (182). This finding
could explain the effect of PFKFB4 overexpression in some cancer
cells, such as the transcription of a key non-oxidative enzyme
of the PPP and the redirection of glycolytic intermediates to the
non-oxidative arm of PPP.
Other inhibitory glycolytic effects that contribute to cancer
development, such as the glycosylation of PFK1 in response
to hypoxia (59) and the Snail repression of PFK-P (60),
redirect glucose flux through the PPP, thereby conferring a
selective growth advantage to cancer cells. Furthermore, FBPase1
overexpression suppresses cancer cell growth (65), its loss
correlating with advanced tumor stage and poor prognosis
(66). Snail can also repress FBPase1 in breast cancer cells
(67), regulating glucose flux toward glycolysis or the PPP by
suppressing either FBPase1 or PFK-P, respectively.
Finally, FBPase1 and PFK-L are part of the “glycosome,” a
complex that modulates the activities of these enzymes and
integrates them with others such as PKM2 and PEPCK1.
Quantitative high-content imaging assays indicate that the
direction of glucose flux between glycolysis, the PPP and
serine biosynthesis seems to be spatially regulated by these
multienzyme complexes in a cluster size-dependent manner,
providing new mechanistic insight into how a cell regulates
the direction of glucose flux between energy metabolism and
anabolic biosynthesis (53).
TARGETING THE TUMOR METABOLIC
ECOSYSTEM
The ability to selectively modulate the metabolism of cancer cells
could have high therapeutic potential. Tumor cells expressing
active oncogenes and/or defects in their tumor suppressors enter
apoptosis when glucose oxidation is limited. Peculiarly, these
same cells often show resistance to other forms of apoptotic
stimuli (radiation and chemotherapy) and the use of glycolytic
inhibitors sensitizes cells to these stimuli and promotes their
death (21, 228, 229).
The dependence of cancer cells on glucose consumption
led to the development of different therapeutic approaches.
Pharmacological inhibition of glycolysis has emerged as a novel
strategy since high glycolytic activity is considered a metabolic
hallmark of cancer (6, 21, 31, 34). HIF-1α overexpression and
the induction of glycolytic isoenzymes, present in many tumors,
have been shown to generate resistance to chemotherapy and
radiation (39, 230, 231). Therefore, inhibiting HIF-1α could be
an important component of cancer therapy (232, 233).
One of the most studied inhibitors has been 2-DG, a glucose
molecule in which the 2-hydroxyl group has been replaced
by hydrogen. 2-DG can be phosphorylated by hexokinase,
but it cannot be metabolized by phosphohexose-isomerase.
Therefore, its intracellular accumulation produces a competitive
inhibition of hexokinases. 2-DG has cytotoxic effects on different
types of cancer cells, especially those overexpressing HIF-1α
and with mitochondrial defects (229, 234). Accordingly, 2-DG
significantly increases the response to treatment with adriamycin
and paclitaxel in human osteosarcoma-bearing mice and of
small cell lung cancer (234). However, the high doses needed to
compete with glucose can induce toxicity (21, 235). Inhibition
of other glycolytic enzymes has been shown to successfully
suppress tumor cell growth, although systemic toxicity and lack
of therapeutic benefit has precluded further development in
numerous preclinical studies (21).
The fact that the PFKFB2-4 genes are overexpressed in
different tumors and are activated by hypoxia and/or oncogenes
indicates that their role is necessary in the development of the
glycolytic phenotype, facilitating the adaptation and survival
of tumor cells in hypoxic micro-environments. Thus, small
molecule inhibitors of PFKFBs could be used to improve the
efficiency and specificity of cancer treatment (161, 236).
The expression of more than one PFKFB isoenzyme in some
cells suggests the use of less specific PFKFB kinase inhibitors
to effectively reduce Fru-2,6-P2 concentrations. In this sense,
targeting of both PFKFB3 and PFKFB4 isoenzymes has been
proposed to be advantageous due to their high expression in some
cancer cells (173). PFKFB isoenzyme inhibitors could also be
used in combination with agents that mimic hypoxic conditions,
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increasing cellular dependence on the upregulation of glycolysis
and PFKFBs. The use of chemotherapeutic drugs together with
PFKFB3 inhibitors may improve response rates as well as
progression-free survival in cancer patients. This is corroborated
by recent data demonstrating that sorafenib resistance in HCC
can be overcome by aspirin, through PFKFB3 inhibition (158).
This type of anti-glycolytic approach substantially differs from
previous cancer treatments that attempted to block glycolysis
entirely and in a permanent way, causing significant adverse
effects. Given that Fru-2,6-P2 is not part of a main metabolic
pathway, and is not a biosynthetic precursor or intermediate
in energy production, its concentration can be independently
controlled, making PFKFB isoenzymes more specific targets.
TIGAR has important functions in the regulation of cell
processes such as apoptosis, autophagy, DNA repair, and the
control of oxidative stress. The elevated levels of TIGAR
expression in some types of tumors (207, 217) and the action
of different therapeutic agents associated with decreased TIGAR
expression, highlight the importance of TIGAR in tumor cell
survival. TIGAR can support tumorigenesis by reducing ROS
production and generating precursors for biosynthesis. These
data indicate that the inhibition of TIGAR might confer
advantages in cancer treatments (29, 186, 206, 221). Moreover,
TIGAR silencing has been shown to increase sensitivity of
glioblastoma cells to radiotherapy (186, 237) and increase cell
death mediated by PFKFB3 inhibition (189).
The current results show that the metabolic phenotype
of tumor cells is heterogeneous and that metabolic coupling
occurs between different cell populations of the TME with
complementary metabolic profiles. The metabolic differences
between tumor and non-tumor cells can potentially be exploited
therapeutically. There are currently no glycolytic inhibitors that
have been approved as anticancer agents (21) and little is known
about the degree of glycolysis inhibition in tumor vs. non-
tumor tissues that can be achieved with glycolytic inhibitors,
but the preclinical results obtained with these molecules
look promising.
The targeting of mitochondrial oxidative metabolism and
antioxidant effectors also hold promise as anticancer strategies.
Arsenic trioxide, an inhibitor of the mitochondrial oxidative
metabolism, has been approved for the treatment of acute
promyelocytic leukemia (238). Metformin, an inhibitor of
complex I of oxidative phosphorylation (239), has been shown
to increase lactate levels and induce apoptosis in a clinical trial
in head and neck squamous cell cancer (240). In the same
clinical trial, metformin was shown to induce CAV1 expression
in CAFs, preventing the metabolic coupling between stromal
and cancer cells (240, 241). Another example of effective anti-
metabolic cancer therapies is the use of N-acetyl cysteine (NAC),
whose antioxidant potential reduced both the proliferation of
cancer cells and the expression of the metabolic coupling
monocarboxylate transporter 4 (MCT4) in stromal cells in a
clinical trial in breast cancer (242). In summary, inhibiting
oxidative metabolism or altering the redox state of tumors appear
as promising approaches for the treatment of cancer.
CONCLUSIONS
In this review, we summarize current knowledge on the
enzymes regulating the Fru-6-P/Fru-1,6-P2 cycle and their role
in cancer and TME cells. PFKFB and TIGAR enzymes control
this cycle and are overexpressed in cancer cells, acting as
prognostic markers. Small molecule inhibitors of PFKFB2-4 in
combination with other drugs could increase the efficiency of
cancer treatment. Further preclinical data on PFKFBs inhibitors
are required to confirm their potential clinical use.
In summary, glycolysis in tumor cells is a complex
phenomenon in which this and other metabolic pathways are
reprogrammed to increase energy production and biomolecular
synthesis required for cell proliferation. Understanding the
regulation of genes and glycolytic isoenzymes in cancer cells
and other cells of the TME will have implications for cancer
diagnosis and prognosis and for the development of more
selective therapies.
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